After exclusion of patients with missing diabetes medication (n = 154), severe renal insufficiency (GFR under 25 ml/min/1,73 m2, n = 76), severe anemia (hemoglobin under 8 g/dl, n = 8) or periinterventional MI (n = 28), 681 patients qualified for analysis and were grouped according to glucose lowering medication: 105 patients in the SGLT2-i and 576 in the no-SGLT2-i group (Fig. 1). Here, SLC5A2 is linked to anemia (phenotype).